Trial Profile
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Bladder 100; READY
- Sponsors Pfizer
- 27 Jan 2024 Results of long-term and exploratory PRO analyses presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 Updated data and subgroup analyses (n=464; from Jan 18, 2021 to Mar 7, 2022) of effectiveness with avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma, presented at the 2024 Genitourinary Cancers Symposium.
- 23 Jan 2024 According to a Merck & Co media release, data of this study will be presented at the 2024 American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.